OVERVIEW

Advances in™ Sickle Cell Disease (SCD): Assessing the Impact of Emerging Agents is organized by Physicians' Education Resource, LLC (PER).

Release Date: September 30, 2019
Expiration Date: September 30, 2020

Accreditation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Sickle cell disease (SCD) is a continually increasing health problem, with approximately 300,000 individuals born annually worldwide with this genetic disease. A defect in the HBB gene on chromosome 11 results in the production of a form of hemoglobin that is less soluble than normal fetal or adult hemoglobin. Lifelong complications resulting from this mutation include anemia, infections, stroke, tissue damage, organ failure, intense painful episodes, and a shorter life expectancy. The intensive treatment needs and unpredictable, debilitating symptoms of people with SCD impose limitations on education, careers, and overall quality of life. Although hematopoietic stem cell transplantation can cure SCD, it is not feasible for most patients. However, new therapies in clinical trials offer targeted, pathophysiologic approaches to improve the quality and duration of life for people with SCD.

Advances in™ Sickle Cell Disease: Assessing the Impact of Emerging Agents will help clinicians apply a guideline-based approach for management of acute and chronic pain as well as the complications of SCD through a series of video interviews with 2 experts in SCD. The essentials of preventive care, multidisciplinary communication of treatment plans, importance of patient education, and efficacy and safety of emerging agents for treatment of SCD will be discussed.

Benefits of Participating:
• Increase knowledge and competence regarding preventive health maintenance and pain treatment care plans for people with SCD
• Learn strategies to effectively manage acute pain episodes in the emergency department
• Build confidence in your knowledge of how to optimally treat various complications of SCD
• Understand the pathophysiologic approaches of emerging and investigative agents

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Summarize current guidelines for management of pain and complications due to SCD in affected patients.
• Evaluate the efficacy and tolerability of agents for SCD being investigated in clinical trials.